Safety study of JX2105 in healthy volunteers
Part of Brain & nervous system clinical trials.
This study tests a new oral drug called JX2105 in healthy people to see how safe it is and how the body handles it. It is a first-in-human phase 1 trial, so participants will help find the right dose and check for any side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your body mass index (BMI) is between 18.5 and 28.
- You are generally healthy and do not have any major medical conditions (like heart, lung, or stomach problems).
- You have not taken any prescription or over-the-counter medications in the last 2 weeks.
- You do not smoke 5 or more cigarettes a day, and you have not had a history of drug or alcohol abuse in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.
This early-stage trial tests a new medicine called JMT206 in healthy people to see if it is safe and how the body handles it. Healthy volunteers, ages 18 to 60, are needed to help researchers learn about the drug's effects and how it moves through the body.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
This early-stage study tests whether a new oral drug (JMKX003801) is safe in healthy volunteers. It helps find the right dose and checks for side effects.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.